Plasma Therapy Market
Plasma therapy is a promising treatment against coronaviruses, and many rare other and serious disorders. The blood that is donated by the donor is processed in a processing facility to obtain plasma. Similarly, for the treatment of coronavirus-infected patients, the plasma is isolated from the donor. The donor is also the patient who has recovered from the infection. The donor plasma consists of antibodies that were generated in order to fight the antigens, i.e., the coronavirus. The blood from the donor is processed in processing centers and then injected into the blood of the patients.
Market Dynamics
Regulatory authorities are interested in conducting clinical trials for the development of new treatment options for coronavirus infected patients. For instance, on April 18, 2020, The Drug Controller General of India (DCGI) accepted the proposal of the Indian Council of Medical Research (ICMR), the apex body in India for the formulation, coordination, and promotion of biomedical research, for conducting clinical trials of convalescent plasma in COVID-19 patients. The ICMR has submitted a list of institutes that are interested in the trial. In convalescent plasma therapy, the antibodies are recovered from the blood of patients who have recovered from COVID-19 and injected into the blood of injected patients. The clinical trial aims to assess the efficacy of convalescent plasma to limit complications in COVID-19 patients and to evaluate the safety of treatment with anti SARS-CoV-2 plasma in coronavirus-infected patients. The rising number of clinical trials is expected to increase treatment options for coronavirus infected patients and spur global plasma therapy market growth during the forecast period.
Companies are receiving approvals from regulatory authorities for the setup of a new manufacturing facility. For instance, in 2021, Takeda Pharmaceutical Company Limited received approval from the U.S Food and Drug Administration (U.S FDA) for its new pharmaceutical manufacturing facility near Covington, Georgia. The facility will produce FLEXBUMIN 25% [Albumin (Human), USP, 25% Solution]. The medicine is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome, and nephrosis, cardiopulmonary bypass surgery, and hemolytic disease of newborns. The new facility will expand the product portfolio of the company which is expected to favor the global plasma therapy market growth during the forecast period.international distributors.
Key features of the study:
Detailed Segmentation:
Table of Contents
*Browse 33 market data tables and 34 figures “Plasma Therapy Market”- Global forecast to 2030
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients